AIMS: Cut-offs for C-reactive protein concentrations have been recommended for risk stratification, but little is known about how these cut-offs predict cardiovascular risk in population-based cohorts. We therefore assessed the association of C-reactive protein levels with cardiovascular mortality in a population-based cohort of 2321 middle-aged men stratified by the presence of cardiovascular disease (CVD) at baseline. METHODS AND RESULTS: C-reactive protein concentrations were categorized according to current recommendations (1 and 3 mg/L). During the 15 year follow-up, 77 men without CVD and 121 men with CVD at baseline died of CVD. In men without CVD at baseline (n=1476), age-adjusted cardiovascular mortality was 4.1-fold higher (95% CI 2.1-8.2) for C-reactive protein levels between 3.0 and 9.9 mg/L at baseline than for C-reactive protein levels <1.0 mg/L. In men with CVD at baseline (n=845), the corresponding age-adjusted cardiovascular mortality was 3.3-fold higher (95% CI 2.0-5.3). Adjustment for conventional CVD risk factors attenuated the risk somewhat. Further adjustment for dietary and lifestyle factors and factors related to insulin resistance did not affect the association. Classification of C-reactive protein by tertiles gave qualitatively similar results, but identified twice as many men at high risk. C-reactive protein levels also predicted overall mortality. CONCLUSION: Currently, recommended cut-offs for C-reactive protein levels identify men at risk for cardiovascular and overall death independently of conventional and other risk factors in a population-based sample of middle-aged men with and without CVD at baseline. Lower cut-offs may better identify men at high risk for cardiovascular death, but improvement of current recommendations will require standardization of C-reactive protein assays.
AIMS: Cut-offs for C-reactive protein concentrations have been recommended for risk stratification, but little is known about how these cut-offs predict cardiovascular risk in population-based cohorts. We therefore assessed the association of C-reactive protein levels with cardiovascular mortality in a population-based cohort of 2321 middle-aged men stratified by the presence of cardiovascular disease (CVD) at baseline. METHODS AND RESULTS:C-reactive protein concentrations were categorized according to current recommendations (1 and 3 mg/L). During the 15 year follow-up, 77 men without CVD and 121 men with CVD at baseline died of CVD. In men without CVD at baseline (n=1476), age-adjusted cardiovascular mortality was 4.1-fold higher (95% CI 2.1-8.2) for C-reactive protein levels between 3.0 and 9.9 mg/L at baseline than for C-reactive protein levels <1.0 mg/L. In men with CVD at baseline (n=845), the corresponding age-adjusted cardiovascular mortality was 3.3-fold higher (95% CI 2.0-5.3). Adjustment for conventional CVD risk factors attenuated the risk somewhat. Further adjustment for dietary and lifestyle factors and factors related to insulin resistance did not affect the association. Classification of C-reactive protein by tertiles gave qualitatively similar results, but identified twice as many men at high risk. C-reactive protein levels also predicted overall mortality. CONCLUSION: Currently, recommended cut-offs for C-reactive protein levels identify men at risk for cardiovascular and overall death independently of conventional and other risk factors in a population-based sample of middle-aged men with and without CVD at baseline. Lower cut-offs may better identify men at high risk for cardiovascular death, but improvement of current recommendations will require standardization of C-reactive protein assays.
Authors: Emily G Kurtz; Paul M Ridker; Lynda M Rose; Nancy R Cook; Brendan M Everett; Julie E Buring; Kathryn M Rexrode Journal: Menopause Date: 2011-01 Impact factor: 2.953
Authors: David E Laaksonen; Leo Niskanen; Kristiina Nyyssönen; Timo A Lakka; Jari A Laukkanen; Jukka T Salonen Journal: Eur Heart J Date: 2008-02-28 Impact factor: 29.983
Authors: Kiran Musunuru; Brian G Kral; Roger S Blumenthal; Valentin Fuster; Catherine Y Campbell; Ty J Gluckman; Richard A Lange; Eric J Topol; James T Willerson; Milind Y Desai; Michael H Davidson; Samia Mora Journal: Nat Clin Pract Cardiovasc Med Date: 2008-08-19
Authors: Giovanni Zuliani; Mario Luca Morieri; Stefano Volpato; Marcello Maggio; Antonio Cherubini; Daniela Francesconi; Stefania Bandinelli; Giuseppe Paolisso; Jack M Guralnik; Luigi Ferrucci Journal: Atherosclerosis Date: 2014-06-10 Impact factor: 5.162
Authors: Walckiria G Romero; Fabrício B Da Silva; Mariana V Borgo; Nazaré S Bissoli; Sonia A Gouvêa; Gláucia R Abreu Journal: Oncologist Date: 2012-04-04
Authors: Pekka Johannes Puustinen; Hannu Koponen; Hannu Kautiainen; Pekka Mäntyselkä; Mauno Vanhala Journal: Eur Arch Psychiatry Clin Neurosci Date: 2010-08-14 Impact factor: 5.270
Authors: Veena S Rao; Natesha B Kadarinarasimhiah; Shibu John; Sridhara Hebbagodi; Jayashree Shanker; Vijay V Kakkar Journal: Int J Vasc Med Date: 2010-06-28